CompaniesGrunenthal

Grunenthal

active

Quito, Ecuador

Founded 1946

Website

About

Small molecules

Areas of Focus

Categories

Small Molecule PharmaceuticalSouth America

Clinical Trials (100)

View all

Total Trials

100

As Lead Sponsor

As Collaborator

Total Enrollment

34,127

By Phase

PHASE4: 5PHASE3: 43PHASE1: 28PHASE2: 14NA: 1PHASE2/PHASE3: 2

By Status

COMPLETED: 74TERMINATED: 18WITHDRAWN: 4RECRUITING: 3UNKNOWN: 1

Clinical Trials Pipeline99 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Today

NCT03951402

Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2003

Completion: Aug 31, 2003

NCT03745404

A Study With Lido-Patch and Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN)

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 29, 2003

Completion: Jun 30, 2004

NCT03765697

A Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic Neuralgia

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 16, 2003

Completion: Feb 12, 2009

NCT03765697

NCT03765801

A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 22, 2003

Completion: Dec 11, 2003

NCT03951987

Investigation How CG5503 is Taken up and Excreted From the Body After 2 Minutes Intravenous Infusion With and Without Oral Co-administration of Charcoal

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 29, 2004

Completion: Apr 30, 2004

NCT03770234

Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 5, 2004

Completion: May 26, 2004

NCT00745069

Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis

Phase: Phase 2

Role: Collaborator

Start: Jul 31, 2004

Completion: Aug 31, 2005

NCT03776110

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GRT9906 Prolonged Release Tablets After Dose Escalation in Healthy Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 15, 2004

Completion: Mar 23, 2005

NCT04016051

Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 22, 2004

Completion: Dec 23, 2004

NCT03761407

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 30, 2004

Completion: Jul 26, 2005

NCT00806247

A Randomized, Double-Blind, Parallel-Arm, Placebo and Active Controlled Dose-Ranging Study of the Efficacy and Safety of Multiple Doses of Tapentadol IR for Postoperative Pain Following Bunionectomy Surgery

Phase: Phase 2

Role: Collaborator

Start: Jan 31, 2005

Completion: Aug 31, 2005

NCT03956134

Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2005

Completion: Jun 30, 2005

NCT03783910

Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia

Phase: Phase 2

Role: Lead Sponsor

Start: Sep 19, 2005

Completion: Oct 20, 2006

NCT03979989

Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 28, 2005

Completion: Nov 16, 2005

NCT03785613

Clinical Pilot Study in Healthy Men to Characterize the Uptake of Buprenorphine Into and Its Elimination From the Body After Topical Application of Two New Forms of a Skin Patch in Comparison to a Reference Patch

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 7, 2005

Completion: Mar 14, 2006

NCT03765658

A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure to Investigate the Safety and Tolerability of GRT0151Y and to Find Out Which Single Dose of the Compound is Maximally Tolerated

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 20, 2006

Completion: Mar 2, 2006

NCT00364546

A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain

Phase: Phase 3

Role: Collaborator

Start: Jul 31, 2006

Completion: Jul 31, 2007

NCT00310908

Comparison Between Tramadol Hcl and Other Analgesics in the Treatment of Renal Colic

Phase: Phase 4

Role: Collaborator

Start: Sep 30, 2006

Completion: Feb 28, 2009

NCT00387777

Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2006

Completion: Dec 31, 2006

NCT00388219

Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2006

Completion: Nov 30, 2006

NCT00361582

A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery

Phase: Phase 3

Role: Collaborator

Start: Oct 31, 2006

Completion: Aug 31, 2007

NCT00364533

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

Phase: Phase 3

Role: Collaborator

Start: Oct 31, 2006

Completion: Dec 31, 2007

NCT00361504

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Phase: Phase 3

Role: Collaborator

Start: Nov 30, 2006

Completion: Jul 31, 2008

NCT00414349

Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 31, 2006

Completion: Mar 31, 2008

NCT00421928

Tapentadol (CG5503)

Phase: Phase 3

Role: Collaborator

Start: Jan 31, 2007

Completion: Dec 31, 2008

NCT00460785

Bioequivalence Trial of a New Opioid Combination Compared to Reference

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 28, 2007

Completion: Mar 31, 2007

NCT00449176

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Phase: Phase 3

Role: Collaborator

Start: Feb 28, 2007

Completion: May 31, 2008

NCT00455520

A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy

Phase: Phase 3

Role: Collaborator

Start: Apr 30, 2007

Completion: Aug 31, 2008

NCT00469053

Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID: 855509)

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2007

Completion: Nov 30, 2007

NCT00469404

Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID 297307)

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2007

Completion: Nov 30, 2007

NCT00478023

A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2007

Completion: Apr 30, 2008

NCT03768024

A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 21, 2007

Completion: Oct 25, 2007

NCT00486811

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2007

Completion: Jul 31, 2008

NCT00505414

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2007

Completion: May 31, 2009

NCT00487435

An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

Phase: Phase 3

Role: Collaborator

Start: Jun 30, 2007

Completion: Jun 30, 2009

NCT00472303

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2007

Completion: Jun 30, 2012

NCT00472303

NCT00609466

A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 30, 2007

Completion: Feb 29, 2008

NCT00594516

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

Phase: Phase 3

Role: Collaborator

Start: Dec 31, 2007

Completion: May 31, 2008

NCT00613938

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

Phase: Phase 3

Role: Collaborator

Start: Feb 29, 2008

Completion: Oct 31, 2008

NCT00771758

Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

Phase: Phase 3

Role: Collaborator

Start: Sep 30, 2008

Completion: Dec 31, 2009

NCT00784277

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Phase: Phase 3

Role: Collaborator

Start: Oct 31, 2008

Completion: Jul 31, 2009

NCT00805142

Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants

Phase: Phase 2

Role: Collaborator

Start: Nov 30, 2008

Completion: Jul 31, 2009

NCT00814580

Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery

Phase: Phase 3

Role: Collaborator

Start: Dec 31, 2008

Completion: Mar 31, 2010

NCT00982280

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 30, 2009

Completion: Aug 31, 2010

NCT00983073

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 30, 2009

Completion: Sep 30, 2010

NCT00983385

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 30, 2009

Completion: Jul 6, 2010

NCT00986180

NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain

Phase: Phase 3

Role: Collaborator

Start: Sep 30, 2009

Completion: Dec 31, 2010

NCT00986258

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability

Phase: Phase 3

Role: Lead Sponsor

Start: Oct 30, 2009

Completion: Jan 31, 2011

NCT01056315

A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 30, 2009

Completion: Jan 31, 2011

NCT01043263

Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain

Phase: Phase 2

Role: Lead Sponsor

Start: Dec 31, 2009

Completion: Jun 30, 2011

NCT01041859

A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

Phase: Phase 3

Role: Collaborator

Start: Dec 31, 2009

Completion: Mar 31, 2011

NCT01063868

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Phase: Phase 3

Role: Collaborator

Start: Jan 31, 2010

Completion: Jun 30, 2010

NCT01053845

Study of Integrity of Down Inhibitor Bundle at Patients Suffering of Neuropathic Pain

Phase: Phase 1

Role: Collaborator

Start: Apr 30, 2010

Completion: May 31, 2011

NCT01155986

Lidocaine 5% Medicated Plaster in Chronic Neuropathic Postoperative Pain

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 31, 2010

Completion: Nov 30, 2012

NCT01264887

Tapentadol in Chronic Malignant Tumour Related Pain

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 31, 2011

Completion: May 31, 2014

NCT01352741

Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin

Phase: Phase 4

Role: Lead Sponsor

Start: Mar 31, 2011

Completion: Jan 31, 2012

NCT01390467

Cognitive Impact of Paracetamol in Healthy Volunteers

Phase: Phase 1

Role: Collaborator

Start: Jul 31, 2011

Completion: Jan 31, 2012

NCT01435577

Intravenous Tapentadol in Post-Bunionectomy Pain

Phase: Phase 2

Role: Lead Sponsor

Start: Sep 30, 2011

Completion: Feb 29, 2012

NCT01134536

Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents

Phase: Phase 2

Role: Collaborator

Start: Oct 31, 2011

Completion: Mar 31, 2013

NCT01485094

A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain

Phase: Phase 2

Role: Lead Sponsor

Start: Feb 29, 2012

Completion: Jan 31, 2013

NCT01752322

Efficacy and Tolerability of Lidocaine Plaster for Treatment of Long-term Local Nerve Pain

Phase: Phase 3

Role: Lead Sponsor

Start: Oct 31, 2012

Completion: Jun 30, 2016

NCT01729728

Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 30, 2012

Completion: Feb 28, 2014

NCT01813890

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo

Phase: Phase 3

Role: Collaborator

Start: Jan 31, 2013

Completion: Jan 31, 2014

NCT01838616

Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.

Phase: Phase 4

Role: Lead Sponsor

Start: Apr 30, 2013

Completion: Jan 31, 2014

NCT02842554

"Training Pain Connoisseurs for Efficient Analgesic Proof-of-Concept Studies"

Phase: Phase 4

Role: Collaborator

Start: Aug 31, 2013

Completion: Oct 31, 2015

NCT02225353

Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery

Phase: Phase 2

Role: Lead Sponsor

Start: Sep 2, 2013

Completion: Mar 13, 2017

NCT02221674

Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 5, 2014

Completion: Nov 3, 2016

NCT02081391

A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain

Phase: Phase 3

Role: Lead Sponsor

Start: Feb 19, 2015

Completion: Mar 14, 2019

NCT02151682

A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain

Phase: Phase 2/3

Role: Lead Sponsor

Start: Apr 29, 2015

Completion: Oct 15, 2018

NCT02402530

Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I

Phase: Phase 2/3

Role: Lead Sponsor

Start: Apr 30, 2015

Completion: Nov 30, 2016

NCT03766984

Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 7, 2015

Completion: Jun 23, 2015

NCT02566564

Intra-articular Lopain (MTX-071) Phase I/IIa Study in Chronic Osteoarthritic Knee Joint Pain

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2016

Completion: Jun 30, 2017

NCT02880722

Experience Sampling Method for Symptom Assessment in Irritable Bowel Syndrome

Phase: N/A

Role: Collaborator

Start: Oct 31, 2016

Completion: May 1, 2022

NCT02880722

NCT02972359

Safety of Intravenous Neridronic Acid in CRPS

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 20, 2016

Completion: Jan 9, 2019

NCT03767036

Administration of Tramadol and Ketorolac Separately and Simultaneously to Assess a Potential Pharmacokinetic Interaction

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 5, 2017

Completion: Jun 30, 2017

NCT03714672

Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 26, 2017

Completion: Mar 22, 2018

NCT03137017

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2017

Completion: Nov 30, 2017

NCT03137030

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2017

Completion: Jan 31, 2018

NCT03399435

A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 30, 2018

Completion: Sep 21, 2018

NCT03530345

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

Phase: Phase 3

Role: Lead Sponsor

Start: May 30, 2018

Completion: Jul 31, 2019

NCT03560986

Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2018

Completion: Aug 1, 2019

NCT03765346

A Comparison of How Likely it is That Different Tablets of Oxycodone Will be Broken up and Snorted by Adults Who Sometimes Take Drugs for Pleasure

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 24, 2018

Completion: Nov 5, 2018

NCT03688880

A Clinical Study to Compare MAR-CUTIS With Dermabond Advanced

Phase: N/A

Role: Lead Sponsor

Start: Oct 30, 2018

Completion: Sep 4, 2019

NCT03737656

Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 1, 2018

Completion: May 9, 2019

NCT03778450

Long-term Opioid Therapy, Misuse and Mortality in Patients With Chronic Non-cancer Pain in Germany

Phase: N/A

Role: Collaborator

Start: Dec 5, 2018

Completion: Aug 31, 2019

NCT03794388

Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery

Phase: Phase 3

Role: Collaborator

Start: Mar 19, 2019

Completion: Nov 18, 2022

NCT03905564

A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2019

Completion: Jun 30, 2020

NCT03814993

taPentadol cLinical prAcTice IN belgiUM

Phase: N/A

Role: Collaborator

Start: Jul 29, 2019

Completion: Aug 1, 2021

NCT04001244

Translational Research in Pelvic Pain

Phase: N/A

Role: Collaborator

Start: Sep 1, 2019

Completion: Feb 23, 2023

NCT03834922

Providing Standardized Consented PROMs (Patient Reported Outcome Measures) for Improving Pain Treatment

Phase: N/A

Role: Collaborator

Start: Sep 24, 2019

Completion: Jun 30, 2022

NCT03910738

TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

Phase: Phase 2

Role: Collaborator

Start: Oct 29, 2019

Completion: Dec 31, 2027

NCT03910738

NCT03749733

Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2019

Completion: Dec 31, 2019

NCT04184596

Preferences in Pain Treatment: A Discrete Choice Experiment in Patients With Peripheral Neuropathic Pain (pNP)

Phase: N/A

Role: Collaborator

Start: Feb 11, 2020

Completion: Aug 31, 2020

NCT04835779

Biometric and Biological Data for Diagnosis and Therapy of Pain Patients

Phase: N/A

Role: Collaborator

Start: Oct 10, 2020

Completion: Oct 31, 2023

NCT05248386

Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 26, 2022

Completion: Nov 18, 2024

NCT05377489

Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 15, 2022

Completion: May 15, 2025

NCT05449132

Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 26, 2022

Completion: Aug 15, 2024

NCT05840562

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

Phase: Phase 3

Role: Collaborator

Start: Oct 20, 2023

Completion: Mar 31, 2027

NCT06444919

Capsaicin in Digital Osteoarthritis Versus Control

Phase: Phase 4

Role: Collaborator

Start: Mar 7, 2025

Completion: Jan 1, 2028

Hover over trial bars to see details

Recent Trials

NCT06444919Collaborator

Capsaicin in Digital Osteoarthritis Versus Control

PHASE4Recruiting

120 participants

Started: Mar 7, 2025 · Completed: Jan 1, 2028

NCT05840562Collaborator

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

PHASE3Recruiting

274 participants

Started: Oct 20, 2023 · Completed: Mar 31, 2027

NCT05449132Lead Sponsor

Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

PHASE3Completed

450 participants

Started: Sep 26, 2022 · Completed: Aug 15, 2024

NCT05377489Lead Sponsor

Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

PHASE3Completed

750 participants

Started: Sep 15, 2022 · Completed: May 15, 2025

NCT05248386Lead Sponsor

Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis

PHASE3Completed

469 participants

Started: Aug 26, 2022 · Completed: Nov 18, 2024

View all 100 trials →

Locations (1)

Headquarters

Quito, Ecuador

Map

Loading map...